Highlights:
-
Focused R&D expansion providing core competencies in biosensor
chemistries and bioassay solutions targeting pharma/biopharma
applications for near and long-term portfolio expansion
-
Broadens cell analysis portfolio with addition of complementary
plate reader-based cellular assays
-
Accelerates expansion into pharma/biopharma discovery and in vitro
toxicology screening applications
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 9, 2018--
Agilent Technologies Inc. (NYSE: A) today announced it has acquired
Cork, Ireland-based Luxcel Biosciences ("Luxcel"), a developer of
real-time fluorescence plate-reader based in vitro cell assay
kits. This acquisition expands Agilent's cell analysis portfolio with
the addition of easy-to-use assay kits that are compatible with industry
standard plate-readers.
"Technological advancements allowing researchers to examine cell health
and function kinetically and in real-time are driving global demand for
complete cell analysis solutions," said Todd Christian, General Manager
of Agilent's Cell Analysis Division. "Luxcel's assay kits are optimized
for standard fluorescent plate readers for broad customer application
helping to address this growing demand."
Luxcel is developing a portfolio of in vitro cell-based assay
kits and solutions targeting cell metabolism, drug safety and toxicity,
as well as hypoxia and oxidative stress for a variety of life science
customers from research institutions to pharmaceutical companies.
Scientists use this technology to understand the roll of cell metabolism
across a variety of important research areas including cancer, metabolic
disorders, cardiovascular disease, immunology, and infectious disease.
Agilent entered the cell analysis market in 2015 with the acquisition of
Seahorse Bioscience, a leader in providing specialized instruments and
live-cell, kinetic assays. "Luxcel is highly complementary to our
Seahorse offerings," said Christian. "With this acquisition, we further
extend our leadership in live-cell, kinetic assays accelerating our
expansion into pharmaceutical and biopharma discovery and in vitro
toxicology screening applications."
"We are a young and motivated group," said Richard Fernandes, CEO of
Luxcel. "When Agilent approached us, it was clear to me that we have a
shared passion for innovation designed to enable and support customers.
Together, we have the potential to accelerate new product introductions
by leveraging Agilent's R&D and global commercial infrastructures with
our unique biosensor chemistries and assay development expertise."
Founded in 2002 by Richard Fernandes and Dmitri Papkovsky as a spin out
company from University College Cork and a member of the High Potential
Start Up program at Enterprise Ireland, Luxcel has 12 employees and is
headquartered in Cork, Ireland. The Luxcel team will remain in Cork and
form a dedicated sensor chemistries and bioassay solutions group within
Agilent's Cell Analysis Division. Financial terms of the deal are not
being disclosed.
About Luxcel
Luxcel was founded in 2002 in Co. Cork, Ireland, and is a multi-award
winning provider of cost-effective and easy to use real-time kinetic
fluorescence-based in vitro live-cell test kits, targeting Cell
Metabolism, Drug Safety and Toxicity, and Hypoxia and Oxidative Stress
applications. Our customers range from University research scientists,
to global Pharmaceutical Companies and Contract Research Organizations.
For more information visit our new website www.luxcel.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences,
diagnostics and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to its
customers' most challenging questions. The company generated revenues of
$4.47 billion in fiscal 2017 and employs 13,500 people worldwide.
Information about Agilent is available at www.agilent.com.
Forward-Looking Statements
This news release contains forward-looking statements as defined in the
Securities Exchange Act of 1934 and is subject to the safe harbors
created therein. The forward-looking statements contained herein
include, but are not limited to, information regarding Agilent's future
revenue, earnings and profitability; planned new products; market
trends; the future demand for the company's products and services;
customer expectations; and revenue and non-GAAP earnings guidance for
the first quarter and full fiscal year 2018. These forward-looking
statements involve risks and uncertainties that could cause Agilent's
results to differ materially from management's current expectations.
Such risks and uncertainties include, but are not limited to, unforeseen
changes in the strength of our customers' businesses; unforeseen changes
in the demand for current and new products, technologies and services;
unforeseen changes in the currency markets; customer purchasing
decisions and timing, and the risk that we are not able to realize the
savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces in running its operations
include the ability to execute successfully through business cycles; the
ability to meet and achieve the benefits of its cost-reduction goals and
otherwise successfully adapt its cost structures to continuing changes
in business conditions; ongoing competitive, pricing and gross-margin
pressures; the risk that our cost-cutting initiatives will impair our
ability to develop products and remain competitive and to operate
effectively; the impact of geopolitical uncertainties and global
economic conditions on our operations, our markets and our ability to
conduct business; the ability to improve asset performance to adapt to
changes in demand; the ability of our supply chain to adapt to changes
in demand; the ability to successfully introduce new products at the
right time, price and mix; the ability of Agilent to successfully
integrate recent acquisitions; the ability of Agilent to successfully
comply with certain complex regulations; and other risks detailed in
Agilent's filings with the Securities and Exchange Commission, including
our annual report on Form 10-K for the fiscal year ended October 31,
2017. Forward-looking statements are based on the beliefs and
assumptions of Agilent's management and on currently available
information. Agilent undertakes no responsibility to publicly update or
revise any forward-looking statement.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180109006016/en/
Source: Agilent Technologies Inc.
Agilent Technologies:
EDITORIAL CONTACTS:
Victoria
Wadsworth-Hansen, +1-408-553-2005
+ 45 29336980
(Business)
victoria.wadsworth-hansen@agilent.com
or
Stefanie
Notaney, +1 408-345-8955
(Enterprise)
stefanie.notaney@agilent.com
or
INVESTOR
CONTACT:
Alicia Rodriguez, +1 408-345-8948
alicia_rodriguez@agilent.com